Abstract

Severe Fever with Thrombocytopenia Syndrome (SFTS) is an emerging infectious disease caused by a novel bunyavirus, SFTS virus (SFTSV), with fatal outcome developed in approximately 17% of the cases. Thrombocytopenia is a hallmark feature of SFTS, and associated with a higher risk of fatal outcome, however, the pathophysiological involvement of platelet in the clinical outcome of SFTS remained under-investigated. In the current study, by retrospectively analyzing 1538 confirmed SFTS patients, we observed that thrombocytopenia was associated with enhanced activation of the cytokine network and the vascular endothelium, also with a disturbed coagulation response. The platelet phenotypes were also extensively altered in the process of thrombocytopenia development of SFTS patients. More importantly, all these disturbed host responses were related to the severity of thrombocytopenia, thus were considered to play in a synergistic way to influence the disease outcome. Moreover, the clinical effect of platelet transfusion was assessed by comparing two groups of patients with or without receiving this therapy. As a result, we observed no therapy effect in altering frequencies of fatal outcome, clinical bleeding development, or dynamic change of platelet count during the hospitalization. It’s suggested that platelet supplementation alone acted a minor role in improving disease outcome, therefore new therapeutic intervention to regulate host response should be proposed. The current results revealed some evidence of interrelationship between platelet count and clinical outcome of SFTS disease from the perspective of activation of the cytokine network, the vascular endothelium, and the coagulation/fibrinolysis system. These evaluations might help to attain a better understanding of the pathogenesis and therapy choice in SFTS.

Highlights

  • Severe Fever with Thrombocytopenia Syndrome (SFTS) is an emerging infectious disease, with a wide distribution in 23 provinces in mainland China as well as in other Asian countries [1]

  • Thrombocytopenia in SFTS virus (SFTSV) is a multifactor-process involving a combination of platelet size or morphology alterations, fibrinolysis activation and coagulation abnormalities, increased inflammatory response and endothelial injury

  • Thrombocytopenia is a hallmark feature of SFTS, with its incidence ranging from 62% to 100% among hospitalized patients [6], which is higher than those reported from other viral hemorrhagic fever (VHF), such as Ebola disease or dengue hemorrhagic fever [7, 8]

Read more

Summary

Introduction

Severe Fever with Thrombocytopenia Syndrome (SFTS) is an emerging infectious disease, with a wide distribution in 23 provinces in mainland China as well as in other Asian countries [1]. An extensively wide clinical spectrum was displayed from the SFTSV infected patients, mostly non-specific clinical manifestations, like fever, gastrointestinal symptoms, myalgia, and regional lymphadenopathy. Low platelet counts were associated with and may contribute to mortality in SFTS patients [5], the mechanism underlying this relationship remained obscure. There are common pathogenesis to all VHF, the underlying mechanism differed in each specific disease. The clinical effect of platelet transfusion was further assessed by comparing two groups of patients with or without receiving this therapy.

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.